Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
35.42
+0.07 (0.20%)
At close: Jul 20, 2026, 4:00 PM EDT
34.74
-0.68 (-1.93%)
After-hours: Jul 20, 2026, 7:34 PM EDT
Celldex Therapeutics Employees
Celldex Therapeutics had 198 employees as of December 31, 2025. The number of employees increased by 12 or 6.45% compared to the previous year.
Employees
198
Change (1Y)
12
Growth (1Y)
6.45%
Revenue / Employee
$4,369
Profits / Employee
-$1,432,556
Market Cap
2.78B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 198 | 12 | 6.45% | 198 | 0 |
| Dec 31, 2024 | 186 | 26 | 16.25% | 186 | 0 |
| Dec 31, 2023 | 160 | 12 | 8.11% | 160 | 0 |
| Dec 31, 2022 | 148 | 14 | 10.45% | 148 | 0 |
| Dec 31, 2021 | 134 | 9 | 7.20% | 132 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Beam Therapeutics | 522 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 339 |
| uniQure | 221 |
| Disc Medicine | 154 |
| Kodiak Sciences | 130 |
| AtaiBeckley | 99 |
CLDX News
- 13 hours ago - Celldex price target raised to $100 from $90 at Guggenheim - TheFly
- 5 days ago - Celldex CFO Sam Martin to retire in 2027 - TheFly
- 5 days ago - Celldex Announces Planned Transition of Chief Financial Officer - GlobeNewsWire
- 25 days ago - Celldex Therapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Celldex presents long-term results from Phase 2 study of barzolvolimab - TheFly
- 5 weeks ago - Celldex presents first-in-human results for CDX-622 - TheFly
- 5 weeks ago - Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewsWire
- 5 weeks ago - Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewsWire